MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/v15010137

Медицинская библиотека · Viruses · 2022

Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?

Meunier Lucy, Belkacemi Mohamed, Pageaux George Philippe, Radenne Sylvie, Vallet-Pichard Anaïs, Houssel-Debry Pauline, Duvoux Christophe, Botta-Fridlund Danielle, de Ledinghen Victor, Conti Filomena, Anty Rodolphe, Di Martino Vincent, Debette-Gratien Marilyne, Leroy Vincent, Gerster Theophile, Lebray Pascal, Alric Laurent, Abergel Armand, Dumortier Jérôme, Besch Camille, Montialoux Helene, Samuel Didier, Duclos-Vallée Jean-Charles, Coilly Audrey

Наблюдательное исследованиеМногоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection have been proven safe and effective in cirrhotic patients awaiting liver transplantation (LT). However, in the long term, data remain minimal regarding the clinical impact of viral eradication on patients listed for decompensated cirrhosis or hepatocellular carcinoma (HCC). We aimed to elucidate the clinical outcomes of patients regarding delisting and the evolution of HCC during the long-term follow-up.

METHODS

An observational, multicenter, retrospective analysis was carried out on prospectively collected data from HCV-positive patients treated with an interferon-free regimen while awaiting LT in 18 French hospitals.

RESULTS

A total of 179 patients were included in the study. The indication for LT was HCC in 104 (58.1%) patients and cirrhosis in 75 (41.9%) patients. The sustained virological response was 84.4% and the treatment was well tolerated. At five years, among 75 patients with cirrhosis treated for HCV, 19 (25.3%) were delisted following improvement after treatment. Predictive factors for delisting highlighted an absence of ascites, MELD score ≤ 15, and Child-Pugh score ≤ 7. No patients with refractory ascites were delisted. Among patients with HCC, 82 (78.9%) were transplanted. The drop-out rate was low (6.7%) and few recurrences of HCC after LT were observed.

CONCLUSIONS

DAAs are safe and effective in patients awaiting LT for cirrhosis or HCC. A quarter of patients with cirrhosis can be delisted because of clinical improvement. Predictive factors for delisting, as a result of improvement, may assist prescribers, before initiating HCV infection therapy in the long-term perspective.

Для цитирования: Meunier Lucy, Belkacemi Mohamed, Pageaux George Philippe, Radenne Sylvie, Vallet-Pichard Anaïs, Houssel-Debry Pauline, Duvoux Christophe, Botta-Fridlund Danielle, de Ledinghen Victor, Conti Filomena, Anty Rodolphe, Di Martino Vincent, Debette-Gratien Marilyne, Leroy Vincent, Gerster Theophile, Lebray Pascal, Alric Laurent, Abergel Armand, Dumortier Jérôme, Besch Camille, Montialoux Helene, Samuel Didier, Duclos-Vallée Jean-Charles, Coilly Audrey. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?. Viruses. 2022. DOI: 10.3390/v15010137.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.